Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation

Background and Purpose. Radium-223 dichloride (Xofigo®, Bayer HealthCare Pharmaceuticals Inc.) is the first α-particle emitter therapeutic agent approved by the FDA, with benefits in overall survival and delay in symptomatic skeletal event for patients with metastatic castrate-resistant prostate can...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Nghi C., Shah, Muhammad, Appleman, Leonard J., Parikh, Rahul, Mountz, James M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059539/
https://www.ncbi.nlm.nih.gov/pubmed/27774318
http://dx.doi.org/10.1155/2016/2568031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059539/
https://www.ncbi.nlm.nih.gov/pubmed/27774318
http://dx.doi.org/10.1155/2016/2568031

Ejemplares similares